Stockscreener 앱 받기
126.98
0.13%
0.16
시간 외 거래:
126.98
Novartis Ag Adr 주식(NVS)의 최신 뉴스
Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™ - GlobeNewswire Inc.
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm - sharewise.com
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease - Ariva
What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum? - Morningstar
Sustainable dividends from European stocks poised to benefit from the tariff wars - The Globe and Mail
INCY's Q2 Earnings & Revenues Beat Estimates On Higher Product Sales - Barchart.com
NVS’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Novartis Holds a Strong Branded Drug Portfolio, Supporting Steady Long-Term Growth - Morningstar
Novartis Beats On Q2 Earnings And Sales, CFO Retires, Stock Down - Barchart.com
Novartis ADR earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
Novartis Earnings: Double-Digit Sales Growth Supports Another Upgrade to Full-Year Guidance - Morningstar
Will Key Drugs Maintain Momentum For Novartis In Q2 Earnings? - Barchart.com
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? - Yahoo Finance
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS) - Barchart.com
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study - TradingView
Incyte Gains 9.2% In Three Months: Buy, Hold Or Sell The Stock? - Barchart.com
5 Large Drug Stocks That Are Poised To Ride On Sector Recovery - Barchart.com
NVO Stock Gains After Parvus Asset Management Builds Stake - Barchart.com
The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 22nd year at ASCO 2025 - Barchart.com
Bristol Myers Collaborates With BNTX For Oncology Candidate - Barchart.com
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Why Value Investing Has Worked Better Outside the US - Morningstar
Which Industries are shaken when Trump's tariff stick swings towards the EU? - 富途牛牛
Regeneron Initial Data On Multiple Myeloma Drug Encouraging - Barchart.com
Bybit Gold & FX now supports stock trading: Explore new markets! - Bybit Announcement
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug - Yahoo Finance
1.50%
0.69%
자본화:
|
볼륨(24시간):